61 related articles for article (PubMed ID: 29461610)
1. The effect of DC+CIK combined therapy on rat liver cancer model and its modulatory effect on immune functions.
He W; Huang Z; Zhou S; Huang L; Wang B; Zhu L; Ding Y; Yu YL; Zhang S
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):778-785. PubMed ID: 29461610
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone.
Wang L; Li X; Dong XJ; Yu XL; Zhang J; Cheng ZG; Han ZY; Liu FY; Yu J; Liang P
Technol Health Care; 2024; 32(3):1819-1834. PubMed ID: 38393935
[TBL] [Abstract][Full Text] [Related]
4. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer.
Wang D; Zhang B; Gao H; Ding G; Wu Q; Zhang J; Liao L; Chen H
BMC Cancer; 2014 Apr; 14():251. PubMed ID: 24720900
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer.
Zhong S; Zhang Y; Lu X; Meftahpour V
J Interferon Cytokine Res; 2024 Mar; 44(3):99-110. PubMed ID: 38488758
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced killer cells combined with dendritic cells inhibited liver cancer cells.
Li QY; Shi Y; Huang DH; Yang T; Wang JH; Yan GH; Wang HY; Tang XJ; Xiao CY; Zhang WJ; Zhang M; Wang L; Gong Y; Yang W; Wu XY; Xiang Y
Int J Clin Exp Med; 2015; 8(4):5601-10. PubMed ID: 26131143
[TBL] [Abstract][Full Text] [Related]
7. Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect.
Wei XC; Yang DD; Han XR; Zhao YA; Li YC; Zhang LJ; Wang JJ
Int J Clin Exp Med; 2015; 8(10):19725-30. PubMed ID: 26770637
[TBL] [Abstract][Full Text] [Related]
8. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pancreatic cancer.
Que RS; Lin C; Ding GP; Wu ZR; Cao LP
J Zhejiang Univ Sci B; 2016 May; 17(5):352-60. PubMed ID: 27143262
[TBL] [Abstract][Full Text] [Related]
9. DC-CIK as a widely applicable cancer immunotherapy.
Wang S; Wang X; Zhou X; Lyerly HK; Morse MA; Ren J
Expert Opin Biol Ther; 2020 Jun; 20(6):601-607. PubMed ID: 32033522
[No Abstract] [Full Text] [Related]
10. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of DC-CIK with PADI4 Protein Can Significantly Elevate the Therapeutic Efficiency in Esophageal Cancer.
Liu C; Zheng Y; Tang J; Wang D; Ma Z; Li S; Chang X
J Immunol Res; 2019; 2019():6587570. PubMed ID: 30944835
[TBL] [Abstract][Full Text] [Related]
12. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Chen CL; Pan QZ; Weng DS; Xie CM; Zhao JJ; Chen MS; Peng RQ; Li DD; Wang Y; Tang Y; Wang QJ; Zhang ZL; Zhang XF; Jiang LJ; Zhou ZQ; Zhu Q; He J; Liu Y; Zhou FJ; Xia JC
Oncoimmunology; 2018; 7(4):e1417721. PubMed ID: 29632736
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of Autologous DC-CIK Cells Combined with Other Immune Cells in the Treatment of Hematological Malignancies -Retrospective Study].
Liu HS; Shi J; Liu HB; Ma TT; Li XR; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):983-990. PubMed ID: 31204965
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma.
Zhou Z; Qin H; Weng L; Ni Y
J BUON; 2019; 24(2):615-621. PubMed ID: 31128014
[TBL] [Abstract][Full Text] [Related]
16. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells.
Qin W; Xiong Y; Chen J; Huang Y; Liu T
J Cell Mol Med; 2018 Jul; 22(7):3364-3376. PubMed ID: 29566310
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis.
Cao J; Kong FH; Liu X; Wang XB
World J Gastroenterol; 2019 Jul; 25(27):3649-3663. PubMed ID: 31367163
[TBL] [Abstract][Full Text] [Related]
18. 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary.
Zhang X; Yang J; Zhang G; Song L; Su Y; Shi Y; Zhang M; He J; Song D; Lv F; Wu P; Wang H; Wang T; Zhang Y; Liu H; Lu P
Immunotherapy; 2020 Jan; 12(1):63-74. PubMed ID: 31914839
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
